PHF5A promotes colorectal cancer progression by alternative splicing of TEAD2

Chang, Yue; Zhao, Yulu; Wang, Liya; Mei-juan, WU; He, Chenglong; Huang, Mengxi; Lei, Zengjie; Yang, Jiahe; Han, Siqi; Wang, Bibo; Chen, Yanyan; Liu, Chao; Yu, Hong-Ju; Xue, Lijun; Geng, Jiao; Chen, Yanan; Dai, Tingting; Ren, Lili; Wang, Qin; Liu, Fei; Chen, Xiaoyuan; Chen, Cheng

doi:10.1016/j.omtn.2021.10.025

Cited by 13 publications

(15 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, our findings are consistent with studies showing increased MXEs in cancer vs. normal cells/tissues using rMATS, 45 , 103 , 104 MISO, or SUPPA. 105 – 110 Long-read RNA-seq of tumors reveals expression of full-length transcripts containing MXEs, many unannotated in reference transcriptomes, 111 , 112 supporting the existence of MXE switches in tumors.…”

Section: Limitations Of the Studymentioning

confidence: 99%

MYC regulates a pan-cancer network of co-expressed oncogenic splicing factors

et al. 2022

View full text Add to dashboard Cite

Section: Limitations Of the Studymentioning

confidence: 99%

MYC regulates a pan-cancer network of co-expressed oncogenic splicing factors

et al. 2022

View full text Add to dashboard Cite

“…For example, PHF5A plays a significant role in migrating and invading hepatocellular carcinoma cells 13 , and in breast cancer, PHF5A expression is elevated and effects a lot in tumor formation 5 . Knockdown of PHF5A can inhibit malignant transformation of gastric cancer cell lines, and experiments have shown that the AKT/mTOR signaling pathway works well in this process 14 , while in colorectal cancer, the over-expressed PHF5A has been shown to promote the cancer cells growth and transfer 15 . Here, the action of PHF5A in various cancers was systematically evaluated using multiple public databases.…”

Section: Discussionmentioning

confidence: 99%

“…The PHF5A expression is elevated in many types of cancer, such as breast cancer, colorectal cancer, gastric cancer and hepatocellular carcinoma. This elevation acts a significant role in the onsets and progress of these cancers 5 , 13 – 15 . In this finding, mRNA expression analysis indicated that PHF5A exhibited a notably elevated levels in 21 types of cancer (Fig.…”

Section: Discussionmentioning

confidence: 99%

“…This acetylation enhances the interaction among U2 snRNPs, thereby affecting extensive gene expression as well as pre-mRNA splicing patterns 11 . The abnormal expression of PHF5A in tumors has been observed to be linked to the genesis and progression of cancer in numerous studies 5 , 11 – 15 . However, most studies on PHF5A are confined to one specific type of cancer.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

PHF5A is a potential diagnostic, prognostic, and immunological biomarker in pan-cancer

Ding,

Li,

Zhao

2023

Sci Rep

View full text Add to dashboard Cite

Studying the molecular mechanisms and regulatory functions of genes is crucial for exploring new approaches and tactics in cancer therapy. Studies have shown that the aberrant expression of PHF5A in tumors is linked to the origin and advancement of multiple cancers. However, its role in diagnosis, prognosis, and immunological prediction has not been comprehensively investigated in a pan-cancer analysis. Using several bioinformatic tools, we conducted a systematic examination of the potential carcinogenesis of PHF5A in various tumors from multiple aspects. Our analysis indicated that PHF5A expression varied between normal and tumor tissues and was linked to clinical diagnosis and prognosis in various cancers. The results confirmed a notable variation in the levels of PHF5A promoter methylation among several types of primary tumor and normal tissues and methylation of the PHF5A promoter played a guiding role in prognosis in some cancers. According to our findings, PHF5A played a critical role in tumor immunity and it might be an excellent target for anticancer immunotherapy. To sum up, PHF5A can be used in pan-cancer diagnostics, prognostics, and immunotherapy.

show abstract

“…Abnormal splicing function can lead to tumor-related processes, e.g. , proliferation, angiogenesis, and metastasis[ 96 ]. Spliceosome, a dynamic machinery responsible for splicing, is made of small nuclear ribonucleoproteins (snRNPs; five molecules are known: U1, U2, U4, U5, and U6) and numerous non-snRNP proteins[ 97 , 98 ].…”

Section: Genes With Confirmed Role In Glioblastoma Stemnessmentioning

confidence: 99%

Delineating the glioblastoma stemness by genes involved in cytoskeletal rearrangements and metabolic alterations

Kałuzińska¹,

Kołat²,

Kośla³

et al. 2023

World J Stem Cells

View full text Add to dashboard Cite

Literature data on glioblastoma ongoingly underline the link between metabolism and cancer stemness, the latter is one responsible for potentiating the resistance to treatment, inter alia due to increased invasiveness. In recent years, glioblastoma stemness research has bashfully introduced a key aspect of cytoskeletal rearrangements, whereas the impact of the cytoskeleton on invasiveness is well known. Although non-stem glioblastoma cells are less invasive than glioblastoma stem cells (GSCs), these cells also acquire stemness with greater ease if characterized as invasive cells and not tumor core cells. This suggests that glioblastoma stemness should be further investigated for any phenomena related to the cytoskeleton and metabolism, as they may provide new invasion-related insights. Previously, we proved that interplay between metabolism and cytoskeleton existed in glioblastoma. Despite searching for cytoskeleton-related processes in which the investigated genes might have been involved, not only did we stumble across the relation to metabolism but also reported genes that were found to be implicated in stemness. Thus, dedicated research on these genes in GSCs seems justifiable and might reveal novel directions and/or biomarkers that could be utilized in the future. Herein, we review the previously identified cytoskeleton/metabolism-related genes through the prism of glioblastoma stemness.

show abstract

PHF5A promotes colorectal cancer progression by alternative splicing of TEAD2

Cited by 13 publications

References 48 publications

MYC regulates a pan-cancer network of co-expressed oncogenic splicing factors

MYC regulates a pan-cancer network of co-expressed oncogenic splicing factors

PHF5A is a potential diagnostic, prognostic, and immunological biomarker in pan-cancer

Delineating the glioblastoma stemness by genes involved in cytoskeletal rearrangements and metabolic alterations

Contact Info

Product

Resources

About